Gabelli Healthcare & WellnessRx Trust: directors' dealings · United States · SEC (Form 4)

About Gabelli Healthcare & WellnessRx Trust

The Gabelli Healthcare & WellnessRx Trust (NYSE: GRX) is a U.S.-listed closed-end fund focused on the healthcare and wellness opportunity set. For international investors, GRX is not an operating healthcare company but an actively managed investment company run by Gabelli Funds, LLC, a subsidiary of GAMCO Investors. Its core mandate is long-term capital appreciation, with portfolio exposure typically tied to structural themes across healthcare services, pharmaceuticals, medical products, devices, and broader wellness-related businesses. ([gabelli.com](https://gabelli.com/wp-content/uploads/2026/01/closedEnd_FactSheets-4Q-2025_GRX.pdf)) The fund dates back to 2007, giving it a meaningful operating history through multiple market regimes, including periods of healthcare rotation, interest-rate volatility, and shifts in sentiment toward defensive growth assets. It is based in Rye, New York, United States, within the Gabelli management platform. Importantly for global investors, GRX trades on the NYSE, which provides exchange-listed liquidity and transparency under U.S. market rules. ([stockanalysis.com](https://stockanalysis.com/stocks/grx/company/?utm_source=openai)) GRX’s investment objective is straightforward: seek long-term growth of capital by investing in opportunities presented by the healthcare and wellness industries. That thematic focus gives the fund exposure to secular drivers such as population aging, innovation in therapeutics, rising healthcare spending, and demand for prevention-oriented and quality-of-life products and services. As a closed-end fund, its market price can diverge from net asset value, so investors must evaluate both underlying portfolio performance and the premium/discount dynamic of the listed vehicle. The 2024 annual report showed a slight decline in NAV for the year, while the publicly traded share price performed better, underscoring that distinction. ([gabelli.com](https://gabelli.com/wp-content/uploads/2025/04/GRXAnnualReport.pdf)) From a competitive standpoint, GRX sits in a specialized niche: a healthcare-focused closed-end fund with an established Gabelli brand and an active, security-selection-driven approach. Its appeal is not only sector exposure but also its distribution policy. The fund has paid quarterly distributions on its common shares since June 2012, and in February 2026 it declared a first-quarter cash distribution of $0.17 per share, up from the prior $0.15 level. That matters for income-oriented investors, especially in Europe, where yield consistency and distribution discipline are often central to portfolio construction. ([gabelli.com](https://gabelli.com/wp-content/uploads/2025/04/GRXAnnualReport.pdf)) Recent disclosures also reinforce that GRX remains an active, SEC-reporting listed vehicle rather than a static legacy trust. Its 2026 filings and fund communications indicate continued portfolio management under Gabelli Funds, alongside a reported total net asset base of roughly $233 million at the time of the February 2026 distribution announcement. In practical terms, GRX is best viewed as a niche NYSE-listed U.S. healthcare fund with a long-term growth mandate, a distribution-oriented profile, and sensitivity to both healthcare fundamentals and market pricing of closed-end funds. ([gabelli.com](https://gabelli.com/wp-content/uploads/2026/02/03-26-div_GRX-4.pdf))